Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 armp-20260812xex99d1.htm EX-99.1 Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “C

Armata Pharmaceuticals said it submitted the complete Phase 3 protocol for its AP-SA02 multi-phage therapy to the FDA, addressing End-of-Phase 2 feedback, and completed four engineering runs at its Los Angeles cGMP facility. The Phase 3 superiority study is planned to start in 2H 2026. The company received a $2.5M DoD continuation award. ARMP shares were up 10.27% to $4.97.

Armata Pharmaceuticals (ARMP) said the U.S. FDA agreed to its Initial Pediatric Study Plan for AP-SA02 in pediatric complicated Staphylococcus aureus bacteremia. The iPSP sets a framework to defer pediatric work until adult Phase 3 data, expected to start in H2 2026, then run a single multicenter open-label pediatric trial. ARMP shares closed July 10 at $4.26.

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.